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Abstract
Purpose—Cytochrome b5 (encoded by CYB5A) and NADH cytochrome b5 reductase (encoded 
by CYB5R3) detoxify aromatic and heterocyclic amine mammary carcinogens found in cigarette 
smoke. We hypothesized that CYB5A and CYB5R3 polymorphisms would be associated with 
breast cancer risk in women.
Methods—We characterized the prevalence of 18 CYB5A and CYB5R3 variants in genomic 
DNA from African American (AfrAm) and Caucasian (Cauc) women from the Carolina Breast 
Cancer Study population (1946 cases and 1747 controls), and determined their associations with 
breast cancer risk, with effect modification by smoking.
Results—A CYB5R3 variant, I1M+6T (rs8190370) was significantly more common in breast 
cancer cases (MAF 0.0238) compared to controls (0.0169, P =0.039); this was attributable to a 
higher MAF in AfrAm cases (0.0611) compared to AfrAm controls (0.0441, P=0.046; adjusted 
OR 1.41, CI 0.98-2.04; P=0.062). When smoking was considered, I1M+6T was more strongly 
associated with breast cancer risk in AfrAm smokers (adjusted OR 2.10, 1.08-4.07; P=0.028) 
compared to never-smokers (OR=1.21; 0.77-1.88; P for interaction=0.176). I1M+6T and three 
additional CYB5R3 variants, -251T, I8-1676C, and *392C, as well as two CYB5A variants, 13G 
and I2-992T, were significantly more common in AfrAms compared to Caucs.
Conclusions—CYB5R3 I1M+6 C>T should be considered in future molecular epidemiologic 
studies of breast cancer risk in AfrAms. Further, variants in CYB5A and CYB5R3 should be 
considered in the evaluation of other tumors in AfrAms that are associated with aromatic and 
heterocyclic amine exposures, to include prostate, bladder, and colon cancers.
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Introduction
Breast cancer has a high incidence in industrialized countries, and women who move from 
low-risk to high-risk countries acquire a breast cancer risk of the host country in as little as 
two generations [1,2]. Environmental factors including diet, smoking, and pollutants appear 
to play an etiologic role. The aromatic amine 4-aminobiphenyl (4-ABP), is a mammary 
carcinogen in rodents that is found in cigarette smoke [3,4], and the heterocyclic amine 2-
amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP), is another mammary carcinogen 
found in cigarette smoke and well done meats [5-7]. Both 4-ABP and PhIP lead to DNA 
adducts that have been found in the breast tissue and milk of women [8,9]. These adducts 
have also been correlated with smoking exposures [10,11]. Further, some studies have found 
higher levels of DNA adducts in breast cancer patients versus controls [12,13], although an 
established relationship between these DNA adducts and breast cancer remains to be proven. 
Epidemiologic studies of smoking and breast cancer risk have been mixed, with some 
studies finding modest positive associations [14-20], and other studies yielding no 
association [21-28]. These inconsistent results could be due, in part, to individual differences 
in the disposition of tobacco carcinogens after similar smoking exposures.
Both PhIP and 4-ABP are bioactivated to arylhydroxylamine metabolites [29-31], which 
ultimately form mutagenic DNA adducts (Figure 1). The disposition of these 
arylhydroxylamines appears to vary among individuals, in that exposure of individual 
primary human mammary epithelial cell lines to standard concentrations of PhIP 
hydroxylamine results in more than 75-fold variability in DNA adduct formation [32]. The 
hydroxylamines of PhIP and 4-ABP are reduced back to their parent compounds, which are 
not directly mutagenic, by cytochrome b5 (b5) and NADH cytochrome b5 reductase (b5R) 
[33]. Reduction of arylhydroxylamines by this pathway is substantially more efficient than 
generation of these metabolites by oxidation of the parent compound [34], which suggests 
that variability in the b5/b5R pathway could modulate the amount of arylhydroxylamine 
available for DNA adduct formation.
We have found individual differences in cytochrome b5 and NADH cytochrome b5 
reductase protein expression and arylhydroxylamine detoxification activities in both human 
liver and breast samples, with more than 75-fold variability in activities in 70 breast samples 
from women undergoing reduction mammoplasty or lumpectomy [35,36]. We further found 
polymorphisms in the genes CYB5A and CYB5R3, which encode b5 and b5R, in tissues 
with outlier low protein expression and activities [35,36]. Many of these variants were found 
only or predominantly in African American samples.
Based on these findings, we hypothesized that polymorphisms in CYB5A or CYB5R3 
contribute to breast cancer risk, particularly in women who smoke. We further hypothesized 
that such polymorphisms would be more common in African American compared to 
Caucasian women. The purpose of this study, therefore, was to screen for the prevalence of 
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18 CYB5A and CYB5R3 variants in African American and Caucasian women with breast 
cancer (invasive or carcinoma in situ (CIS)), compared to age-matched unaffected controls, 
using the Carolina Breast Cancer Study population [37], and to determine whether CYB5A 
or CYB5R3 polymorphisms were associated with breast cancer risk in relationship to 
smoking.
Materials and Methods
Carolina Breast Cancer Study population
The Carolina Breast Cancer Study (CBCS) is a case-control study population of women with 
breast cancer from 24 counties of central and eastern North Carolina [37]. Women who were 
diagnosed with invasive breast cancer or CIS between the ages of 20-74 were identified 
through the North Carolina Central Cancer Registry; population-based controls were 
frequency matched to cases by age (within 5 years) and race [37]. Race was self-reported, 
and 144 ancestry informative markers (AIMs) were used to estimate West African genetic 
ancestry and control for population stratification [38]. The majority of subjects in the CBCS 
were Caucasian (Cauc) or African American (AfrAm) [39], with 1.5% of the population 
from Native American, Asian, Hispanic, or multi-racial groups. Only Cauc and AfrAm 
subjects were analyzed in the present study, to include DNA samples from 1946 breast 
cancer cases (742 AfrAm and 1204 Cauc) and 1747 controls (658 AfrAm and 1089 Cauc). 
Smoking history was recorded for all subjects, to include active status, packs per day, 
duration, and time since cessation [27]. Characteristics of CBCS participants included in the 
study are listed in Table 1.
Genotyping
Genomic DNA samples from all women were genotyped for 18 single nucleotide 
polymorphisms (SNPs), 8 in CYB5A (Table 2) and 10 in CYB5R3 (Table 3). SNPs were 
selected based on the following criteria: 1) a variant previously observed in breast or liver 
samples with low protein expression or arylhydroxylamine reduction activities [35,36]; 2) a 
reported non-synonymous cSNP (NCBI SNP database; www.ncbi.nlm.nih.gov/); or 3) a 
reported SNP in a region predicted to affect protein function, splicing, or transcription factor 
or miRNA binding, even if apparently rare. For the latter predictions, the possible effects of 
coding polymorphisms on protein function were evaluated using PMut (mmb.pcb.ub.es/
PMut/), SIFT (sift.jcvi.org/), and PolyPhen-2 (genetics.bwh.harvard.edu/pph2/ index.shtml) 
software. The effects of intronic variants on splicing were modeled with the Human Splicing 
Finder suite of software (HSF, MaxEnt, and ESE Finder; www.umd.be/HSF/). The influence 
of variants on transcription factor binding was predicted with the MATCH program 
(www.bioinfo.de/isb/gcb01/poster/goessling.html) and the ENCODE data base [40] (http://
genome.cse.ucsc.edu/encode/), and the effects of 3′UTR (untranslated region) SNPs on 
miRNA binding were predicted with UTRscan (itbtools.ba.itb.cnr.it/utrscan).
The PCR-based Taqman Genotyping Assay (Applied Biosytems, Foster City, CA) was 
utilized for most polymorphisms, and was performed at the University of North Carolina at 
Chapel Hill. SNPs that failed the Taqman assay were evaluated by pyrosequencing, using 
the PSQTM96MA System (Biotage AB, Uppsala, Sweden), at the University of Wisconsin 
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Carbone Comprehensive Cancer Center. Both SNP screening techniques were validated by 
running positive and negative genomic DNA controls from liver or breast samples, where 
available, in which the allele of interest had been previously established by direct 
sequencing [35,36]. A total of 144 ancestry informative markers (AIMs) were also 
genotyped to estimate African and European ancestry [41]. These AIMs were selected from 
a panel that has been used by others to estimate ancestry in African Americans [42,43].
Data analyses
Prior to association analysis, SNPs were checked for genotyping efficiency and tested for 
deviation from genotype proportions expected within control groups, stratified by race under 
Hardy-Weinberg equilibrium (HWE) conditions using Chi Square testing. Minor allele 
frequencies (MAFs) and genotypes for each SNP were then compared between AfrAm and 
Cauc women in the control groups, and between women with breast cancer and controls 
(both across all subjects and within the two racial groups), using Chi Square testing with P < 
0.05. Breast cancer risk was calculated using unconditional logistic regression (SAS 
software program) in order to quantify the association with CYB5A and CYB5R3 
genotypes, with adjustment for age and African ancestry. An offset term was included in 
models to account for randomized recruitment sampling. The sample size provided 80% 
power to detect odds ratios of 1.2 or greater for alleles with a frequency of 5% or greater in 
the population overall. We also estimated odds ratios stratified by smoking status (ever, 
never). As an exploratory analysis, we modeled multiplicative interactions between 
genotype and smoking using a likelihood ratio test; however, power for testing interactions 
between genotype and smoking, stratified by race, was fairly limited.
Results
Allele detection
Five previously reported CYB5A variants, rs36082929 (-206G>-), rs74339771 (65A>G), 
rs1803366 (155G>A), rs78009726 (178A>G, Thr60Ala), and rs76241580 (*246T>C) were 
not detected in the CBCS population. These rare variants have not been found in population 
screens reported in either the NCBI or the 1000 Genomes databases (www.
1000genomes.org/). Two CYB5R3 variants, rs111154229 (176G>A), and rs76458556 
(890G>A), previously found by direct resequencing of liver cDNA samples [35], were also 
not detected in the CBCS population. Both appear to be rare; 176G>A has not been reported 
in other SNP databases (either NCBI or 1000 Genomes), while 890G>A was reported with 
an MAF of only 0.002 overall (browser.1000genomes.org). All detected alleles were in 
HWE in the AfrAm population. Two variants, rs7284807 (*392 G>C) and rs1790894 (I2 
-992 C>T) were not in HWE in Cauc controls, and were not analyzed further.
Allele frequencies by cancer outcome
Allele frequencies for the remaining 11 variants were compared between breast cancer cases 
and controls, both overall and within racial groups. CYB5R3 I1M+6C>T was significantly 
more common in breast cancer cases compared to controls (MAF 0.0238 versus 0.0169, 
P=0.039), with an odds ratio of 1.42 (0.99-2.04), P=0.057. This difference was attributable 
to a significantly higher prevalence in AfrAm cases compared to AfrAm controls (MAF 
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0.0611 versus 0.0441, P=0.046; OR 1.41 (0.98-2.04); P=0.062, Tables 4 and 5). An 
elevated, but very imprecise odds ratio was found between I1M+6C>T and breast cancer in 
Cauc women (OR 1.57 (0.13-19.71), P=0.726)), due to very low allele frequencies. No other 
variant was significantly different between cases and controls, either in the population 
overall or as stratified by race.
Breast cancer risk was further evaluated for I1M+6C>T in relationship to smoking status 
(Table 5). Because of relatively low numbers of carriers for most alleles, smoking status was 
collapsed by necessity into two separate categories, ever smokers and never smokers 
(defined as less than 100 lifetime cigarettes). The CYB5R3 I1M+6T allele was significantly 
associated with breast cancer risk in ever smokers (OR 1.97, 95% CI 1.03-3.77), and in 
particular in AfrAm ever smokers (OR 2.10, 95% CI 1.08-4.07). This relationship was not as 
strong among AfrAm never smokers (OR 1.21, 95% CI 0.77-1.88; P = 0.4096). In Cauc 
women, allele frequencies for I1M+6T were too low to determine risk when stratified by 
smoking status (Table 5). Interactions between the I1M+6 genotype and smoking for breast 
cancer risk were also modeled. The P value for interactions was 0.162 for all subjects and 
0.176 for the AfrAm population.
In silico analysis of the 1M+6 locus
In silico analyses were performed on the IM+6 polymorphic locus. The reference C allele 
was conserved among primates, rodents, and rabbits (UCSC Genome Browser; 
genome.ucsc.org). The T variant was predicted by Human Splicing Finder to create a cryptic 
splice site 4 nucleotides downstream from the natural donor site at the junction between 
alternative exon 1M and intron 1. The resulting mRNA was predicted to be 4 bp longer than 
wild type (NCBI Ref Seq ID: NM_000398), and to create a frame-shift leading to a 
premature stop codon. Further, this transcript was predicted to undergo nonsense-mediated 
decay, since the predicted stop codon was located more than 50 nucleotides upstream of the 
exon 2/3 splice junction [44].
Allele frequencies by race
Minor allele frequencies for CYB5A and CYB5R3 SNPs by race are shown in Table 4. I1M
+6C>T was almost 90-fold more common in AfrAm compared to Cauc controls (MAF 
0.0441 versus 0.0005, P < 0.0001). Three other CYB5R3 variants were also over-
represented in AfrAm versus Cauc controls. The promoter variant -251G>T was ∼140-fold 
more prevalent in AfrAm women (MAF 0.0727; P < 0.0001), and was predicted to delete 
binding sites for several transcription factors (Table 3). The intronic SNP I8-1676T>C was 
more than 100-fold more prevalent in AfrAm women (MAF 0.1531, P < 0.0001), and was 
within an experimentally demonstrated binding site for the DNA repair protein RAD21. The 
3′UTR variant *392G>C was found with an MAF of 0.1353 in AfrAm women, but is of 
unknown functional significance.
As for CYB5A, two variants were more prevalent in AfrAm women (Table 4). The intronic 
SNP I2-992T was found with a MAF of 0.1689 in AfrAm controls, and was predicted to be 
within a binding site for NF-κB. The non-synonymous cSNP 13T>G (Ser5Ala) was found 
only in AfrAm subjects, but with a very low frequency (MAF 0.0069).
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4-ABP and PhIP are mammary carcinogens that are found in tobacco smoke. These 
chemicals are bioactivated to their arylhydroxylamine metabolites, which lead to DNA 
adducts that are thought to initiate cancer [29-31]. Cytochrome b5 and its reductase oppose 
this bioactivation step; this pathway, found in both liver and breast tissues, is a potential 
source of individual variability in response to these carcinogens [33,34]. We hypothesized 
that variants in the CYB5A and CYB5R3 genes encoding this pathway would be associated 
with breast cancer risk in women who smoke. We further hypothesized that several CYB5A 
and CYB5R3 variants that we previously found only in African American liver and breast 
tissues (Table 2) would be over-represented in AfrAm women in this larger population.
Of the 18 variants screened, an intronic variant in CYB5R3, I1M+6T (rs8190370) was 
significantly more common in breast cancer cases compared to controls, and this was 
attributable to a significantly higher allele frequency in AfrAm cases compared to AfrAm 
controls. When stratified by smoking, I1M+6T was more strongly associated with breast 
cancer, particularly in AfrAm women where the allele was most prevalent. When we further 
analyzed for an interaction between the I1M+6T allele and smoking, the P values were not 
significant for an interaction on the multiplicative scale. However, given the relatively low 
allele frequencies overall, the study as underpowered to detect such an interaction.
In the control subjects in this CBCS survey, I1M+6C>T was observed with an MAF that 
was almost 90-fold higher in AfrAm versus Cauc women. This variant was previously 
observed in the heterozygous state in 1 of 69 livers (unpublished data from Sacco et al. 
2010), and 2 of 70 breast samples [36] all samples were from AfrAm subjects, with b5R 
immunoreactive protein expression below the 95% confidence interval for each tissue. The 
reference C allele is conserved among mammals, and the T variant is predicted to change the 
splice site at the first intron-exon splice junction of CYB5R3, leading to a truncated 
transcript. The CYB5R3 I1M+6C>T variant may therefore lead to impaired b5R expression, 
and this polymorphism merits further functional characterization.
The risk of breast cancer in African American versus Caucasian women has been the subject 
of a number of studies, most of which have focused on differences in clinical presentation, 
tumor behavior, and dietary and hormonal exposures [50,51]. As for interactions between 
smoking and race, a 1992 study found an association between smoking and breast cancer in 
white women, but not black women [52]. In the CBCS population used in the present study, 
smoking was previously found to be a more significant risk factor for breast cancer in 
AfrAm than Cauc women, based on both duration of active smoking and time since smoking 
cessation [53,54]. This relationship was found to be stronger when considering multiple 
polymorphisms in nucleotide excision repair (NER) genes [54], which mediate repair of 
smoking-induced DNA adducts. These studies, together with our data, suggest that the 
higher risk associated with smoking among AfrAm women may be partly due to genetic 
variation in pathways that mediate both the detoxification of arylamine and heterocyclic 
amine tobacco carcinogens and the repair of resulting DNA adducts.
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Overall, CYB5A and CYB5R3 polymorphisms were fairly uncommon, with MAF values ≤ 
0.15 for most variants. This may reflect evolutionary pressure to conserve the function of 
this pathway, which has an important endogenous role in maintaining hemoglobin in its 
functional, reduced state [45-47]. However, several variants were more prevalent in AfrAm 
women compared to Cauc women. In addition to I1M+6T, the CYB5R3 promoter SNP 
-251G>T was more than 140-fold more prevalent in AfrAm women, with an MAF (∼0.070) 
that was similar to that reported for native African populations (browser.1000genomes.org). 
We previously observed this variant in a heterozygous liver with outlier low b5R expression 
and hydroxylamine reduction activity (Table 3). This SNP is predicted to eliminate 
VDR/CAR/PXR binding sites, and functional analysis of this SNP using a luciferase 
reported assay showed a 58% decrease in expression compared to the wild type promoter 
(data not shown).
A third CYB5R3 variant, I8-1676T>C, which was found with > 100-fold higher allele 
frequency in AfrAm women, is within a binding site for RAD21, which could affect DNA 
double-strand-break repair. A final CYB5R3 variant, *392G>C, was found with >30-fold 
higher frequency in AfrAm women. This variant was previously observed in haplotype 
configuration in 8 breast samples, all from AfrAm women. [36] Although it was not 
predicted by UTRscan to affect miRNA binding, this 3′UTR variant merits functional 
characterization because of its relatively high prevalence.
Two CYB5A variants also had significantly higher allele frequencies in AfrAm women. One 
coding SNP, 13T>G (Ser5Ala) was exclusively found in AfrAm subjects, albeit at a very 
low frequency. This variant was also reported with low frequency in native Africans (MAF 
0.020) and was absent in European subjects in the 1000 Genomes Project (browser.
1000genomes.org). Another CYB5A variant, I2-992C>T, was observed with >20-fold 
higher allele frequency in AfrAm women (MAF 0.169); this frequency is intermediate 
between those reported for African (0.201) and European (0.007) populations (browser.
1000genomes.org). I2-992C>T was predicted to be within a binding site for NF-κB, which 
could affect gene expression [48,49]. There are several limitations to this study. Because of 
low allele frequencies, some of the estimates were imprecise and required that the smoking 
data be categorized as ever or never smokers. This did not allow consideration of age at 
smoking initiation, cigarette dosage and duration, or exposure to passive smoke [54,55]. Our 
findings should be confirmed in a larger AfrAm population to allow inclusion of more 
detailed smoking categories. In addition, samples were not fully re-sequenced, so other, 
potentially novel polymorphisms or haplotype associations within CYB5A and CYB5R3 
were not evaluated. Finally, we have previously found substantial individual variability in 
b5 and b5R protein expression, as well as 4-ABP hydroxylamine reduction activities in 
human breast, which could not be attributed to genetic polymorphisms alone [36]. This 
suggests that there may be tissue-specific, environmentally induced, or epigenetic regulation 
of this pathway that may also influence breast detoxification of carcinogenic 
arylhydroxylamines. This possibility deserves further study in breast tissues from women 
with and without breast cancer.
In summary, we found that the CYB5R3 variant I1M+6 C>T was significantly over-
represented in women with breast cancer, in particular AfrAm women. Further, there was a 
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suggestion of an interaction of this variant and smoking among AfrAm women. This 
intronic variant is predicted to cause aberrant splicing of the CYB5R3 transcript, which may 
lead to decreased b5R expression and impaired detoxification of carcinogenic 
arylhydroxylamine metabolites. The CYB5R3 I1M+6 C>T variant should be considered in 
the molecular epidemiology studies of breast cancer risk in AfrAms. In addition, this and 
other variants in CYB5A and CYB5R3 that are over-represented in AfrAm subjects should 
be considered in etiologic studies of prostate, bladder, and colon cancers, which are also 
associated with exposure to arylamine and heterocyclic amine carcinogens [56-58].
Acknowledgments
The authors thank Jessica Tse, at the Mammalian Genotyping Core at the University of North Carolina at Chapel 
Hill, for genotype analyses; and Dr. Elim Lau at the University of Wisconsin Carbone Comprehensive Cancer 
Center (UWCCC) for performing pyrosequencing. The authors also acknowledge the kind assistance of Dr. Richard 
Weinshilboum, whose laboratory performed initial screening of selected allele frequencies in Coriell DNA samples 
from African American subjects. Finally, the PI thanks Dr. Andrew Olshan, who was instrumental in the 
completion of this manuscript following the unexpected death of Dr. Robert Millikan.
Financial support: This work was supported by the Prevent Cancer Foundation and R01 GM61753 from the 
National Institutes of Health. The Carolina Breast Cancer Study was funded by the Specialized Program of 
Research Excellence (SPORE) in Breast Cancer at UNC (NIH/NCI P50-CA58223) and the Lineberger 
Comprehensive Cancer Center Core Grant (P30-CA16086).
Grant support: This study was supported by a grant from the Prevent Cancer Foundation, and in part by R01 
GM61753 from the National Institutes of Health. Kristina Blanke was supported by an NIH/NIEHS training grant 
in Molecular and Environmental Toxicology (T32 ES007015). The Carolina Breast Cancer Study is supported by a 
Program of Research Excellence (SPORE) in Breast Cancer (NIH/NCI P50-CA58223). The University of 
Wisconsin Carbone Comprehensive Cancer Center (UWCCC) facilities are supported by NIH/NCI P30 CA014520. 
Dr. Richard Weinshilboum's contributions to preliminary data were supported by NIH/NIGMS grant U19 
GM061388.
References
1. Kelsey JL, Horn-Ross PL. Breast cancer: magnitude of the problem and descriptive epidemiology. 
Epidemiol Rev. 1993; 15:7–16. [PubMed: 8405214] 
2. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancer-epidemiology, risk 
factors, and genetics. BMJ. 2000; 321:624–8. [PubMed: 10977847] 
3. Hecht SS. Tobacco smoke carcinogens and breast cancer. Environ Mol Mutagen. 2002; 39:119–26. 
[PubMed: 11921179] 
4. Shan L, Yu M, Snyderwine EG. Gene expression profiling of chemically induced rat mammary 
gland cancer. Carcinogenesis. 2005; 26:503–9. [PubMed: 15528215] 
5. Ghoshal A, Preisegger KH, Takayama S, Thorgeirsson SS, Snyderwine EG. Induction of mammary 
tumors in female Sprague-Dawley rats by the food-derived carcinogen 2-amino-1-methyl-6-
phenylimidazo[ 4,5-b]pyridine and effect of dietary fat. Carcinogenesis. 1994; 15:2429–33. 
[PubMed: 7955086] 
6. Ito N, Hasegawa R, Sano M, Tamano S, Esumi H, Takayama S, et al. A new colon and mammary 
carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). 
Carcinogenesis. 1991; 12:1503–6. [PubMed: 1860171] 
7. Snyderwine EG, Thorgeirsson UP, Venugopal M, Roberts-Thomson SJ. Mammary gland 
carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Sprague-Dawley rats on 
high- and low-fat diets. Nutr Cancer. 1998; 31:160–7. [PubMed: 9795967] 
8. Lightfoot TJ, Coxhead JM, Cupid BC, Nicholson S, Garner RC. Analysis of DNA adducts by 
accelerator mass spectrometry in human breast tissue after administration of 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine and benzo[a]pyrene. Mutat Res. 2000; 472:119–27. [PubMed: 
11113704] 
Blanke et al. Page 8






















9. Pfau W, Stone EM, Brockstedt U, Carmichael PL, Marquardt H, Phillips DH. DNA adducts in 
human breast tissue: association with N-acetyltransferase-2 (NAT2) and NAT1 genotypes. Cancer 
Epidemiol Biomarkers Prev. 1998; 7:1019–25. [PubMed: 9829711] 
10. Faraglia B, Chen S, Gammon M, Zhang Y, Teitelbaum S, Neugat A, et al. Evaluation of 4-
aminobiphenyl-DNA adducts in human breast cancer: the influence of tobacco smoke. 
Carcinogenesis. 2003; 24:719–25. [PubMed: 12727801] 
11. Firozi PF, Bondy ML, Sahin AA, Chang P, Lukmanji F, Singletary E, et al. Aromatic DNA 
adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Carcinogenesis. 
2002; 23:301–6. [PubMed: 11872636] 
12. Li D, Wang M, Dhingra K, Hittelman WN. Aromatic DNA adducts in adjacent tissues of breast 
cancer patients: clues to breast cancer etiology. Cancer Res. 1996; 56:287–93. [PubMed: 8542582] 
13. Zhu J, Chang P, Bondy ML, Sahin AA, Singletary SE, Takahashi S, et al. Detection of 2-amino-1-
methyl-6-phenylimidazo[4,5-b]-pyridine-DNA adducts in normal breast tissues and risk of breast 
cancer. Cancer Epidemiol Biomarkers Prev. 2003; 12:830–7. [PubMed: 14504191] 
14. Bennicke K, Conrad C, Sabroe S, Sorensen HT. Cigarette smoking and breast cancer. BMJ 
(Clinical research). 1995; 310:1431–3. [PubMed: 7613275] 
15. Brownson RC, Blackwell CW, Pearson DK, Reynolds RD, Richens JW Jr, Papermaster BW. Risk 
of breast cancer in relation to cigarette smoking. Arch Intern Med. 1988; 148:140–4. [PubMed: 
3337590] 
16. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Cigarette smoking and risk of fatal 
breast cancer. American Journal of Epidemiology. 1994; 139:1001–7. [PubMed: 8178779] 
17. Lash TL, Aschengrau A. Active and passive cigarette smoking and the occurrence of breast cancer. 
Am J Epidemiol. 1999; 149:5–12. [PubMed: 9883788] 
18. Marcus PM, Newman B, Millikan RC, Moorman PG, Baird DD, Qaqish B. The associations of 
adolescent cigarette smoking, alcoholic beverage consumption, environmental tobacco smoke, and 
ionizing radiation with subsequent breast cancer risk (United States). Cancer Causes Control. 
2000; 11:271–8. [PubMed: 10782661] 
19. Meara J, McPherson K, Roberts M, Jones L, Vessey M. Alcohol, cigarette smoking and breast 
cancer. Brit J Cancer. 1989; 60:70–3. [PubMed: 2803918] 
20. Terry PD, Rohan TE. Cigarette smoking and the risk of breast cancer in women: a review of the 
literature. Cancer Epidemiol Biomarkers Prev. 2002; 11:953–71. [PubMed: 12376493] 
21. Baron JA, Byers T, Greenberg ER, Cummings KM, Swanson M. Cigarette smoking in women 
with cancers of the breast and reproductive organs. Journal of the National Cancer Institute. 1986; 
77:677–80. [PubMed: 3462409] 
22. Braga C, Negri E, La Vecchia C, Filiberti R, Franceschi S. Cigarette smoking and the risk of breast 
cancer. Eur J Cancer Prev. 1996; 5:159–64. [PubMed: 8818604] 
23. Chu SY, Stroup NE, Wingo PA, Lee NC, Peterson HB, Gwinn ML. Cigarette smoking and the risk 
of breast cancer. Am J Epidemiol. 1990; 131:244–53. [PubMed: 2404408] 
24. Egan, KM.; Stampfer, MJ.; Hunter, D.; Hankinson, S.; Rosner, BA.; Holmes, M., et al. 
Epidemiology. Vol. 13. Cambridge, Mass: 2002. Active and passive smoking in breast cancer: 
prospective results from the Nurses′ Health Study; p. 138-45.
25. Field NA, Baptiste MS, Nasca PC, Metzger BB. Cigarette smoking and breast cancer. Int Journal 
Epidemiol. 1992; 21:842–8.
26. Hunter DJ, Hankinson SE, Hough H, Gertig DM, Garcia-Closas M, Spiegelman D, et al. A 
prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. 
Carcinogenesis. 1997; 18:2127–32. [PubMed: 9395212] 
27. Millikan RC, Pittman GS, Newman B, Tse CK, Selmin O, Rockhill B, et al. Cigarette smoking, N-
acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998; 
7:371–8. [PubMed: 9610785] 
28. Vatten LJ, Kvinnsland S. Cigarette smoking and risk of breast cancer: a prospective study of 
24,329 Norwegian women. Eur J Cancer. 1990; 26:830–3. [PubMed: 2145906] 
29. Bartsch, H. Metabolic activation of aromatic amines and azo dyes. Vol. 1. IARC Sci Pub; 1981. p. 
13-30.
Blanke et al. Page 9






















30. Fan L, Schut HA, Snyderwine EG. Cytotoxicity, DNA adduct formation and DNA repair induced 
by 2-hydroxyamino-3-methylimidazo[4,5-f]quinoline and 2-hydroxyamino-1-methyl-6-
phenylimidazo[4,5-b]pyridine in cultured human mammary epithelial cells. Carcinogenesis. 1995; 
16:775–9. [PubMed: 7728954] 
31. Turesky RJ, Lang NP, Butler MA, Teitel CH, Kadlubar FF. Metabolic activation of carcinogenic 
heterocyclic aromatic amines by human liver and colon. Carcinogenesis. 1991; 12:1839–45. 
[PubMed: 1934265] 
32. Stone EM, Williams JA, Grover PL, Gusterson BA, Phillips DH. Interindividual variation in the 
metabolic activation of heterocyclic amines and their N-hydroxy derivatives in primary cultures of 
human mammary epithelial cells. Carcinogenesis. 1998; 19:873–9. [PubMed: 9635877] 
33. Kurian JR, Chin NA, Longlais BJ, Hayes KL, Trepanier LA. Reductive detoxification of 
arylhydroxylamine carcinogens by human NADH cytochrome b5 reductase and cytochrome b5. 
Chem Res Toxicol. 2006; 19:1366–73. [PubMed: 17040106] 
34. King R, Teitel C, Shaddock J, Casciano D, Kadlubar F. Detoxification of carcinogenic aromatic 
and heterocyclic amines by enzymatic reduction of the N-hydroxy derivative. Cancer Letters. 
1999; 143:167–71. [PubMed: 10503898] 
35. Sacco JC, Trepanier LA. Cytochrome b5 and NADH cytochrome b5 reductase: genotype-
phenotype correlations for hydroxylamine reduction. Pharmacogenet Genomics. 2010; 20:26–37. 
[PubMed: 19997042] 
36. Rhoads K, Sacco JC, Drescher N, Wong A, Trepanier LA. Individual variability in the 
detoxification of carcinogenic arylhydroxylamines in human breast. Toxicol Sci. 2011; 121:245–
56. [PubMed: 21447608] 
37. Newman B, Moorman PG, Millikan R, Qaqish BF, Geradts J, Aldrich T, et al. The Carolina Breast 
Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer 
Res Treat. 1995; 35:51–60. [PubMed: 7612904] 
38. Nyante SJ, Gammon MD, Kaufman JS, Bensen JT, Lin DY, Barnholtz-Sloan JS, et al. Common 
genetic variation in adiponectin, leptin, and leptin receptor and association with breast cancer 
subtypes. Breast Cancer Res Treat. 2011; 129:593–606. [PubMed: 21516303] 
39. Moorman PG, Newman B, Millikan RC, Tse CK, Sandler DP. Participation rates in a case-control 
study: the impact of age, race, and race of interviewer. Annal Epidemiol. 1999; 9:188–95.
40. ENCODE Project Consortium. A user's guide to the encyclopedia of DNA elements (ENCODE). 
PLoS biology. 2011; 9:e1001046. [PubMed: 21526222] 
41. Barnholtz-Sloan JS, Shetty PB, Guan X, Nyante SJ, Luo J, Brennan DJ, et al. FGFR2 and other 
loci identified in genome-wide association studies are associated with breast cancer in African-
American and younger women. Carcinogenesis. 2010; 31:1417–23. [PubMed: 20554749] 
42. Barnholtz-Sloan JS, McEvoy B, Shriver MD, Rebbeck TR. Ancestry estimation and correction for 
population stratification in molecular epidemiologic association studies. Cancer Epidemiol 
Biomarkers Prev. 2008; 17:471–7. [PubMed: 18349264] 
43. Tian C, Hinds DA, Shigeta R, Kittles R, Ballinger DG, Seldin MF. A genomewide single-
nucleotide-polymorphism panel with high ancestry information for African American admixture 
mapping. Am J Hum Genet. 2006; 79:640–9. [PubMed: 16960800] 
44. Schell T, Kulozik AE, Hentze MW. Integration of splicing, transport and translation to achieve 
mRNA quality control by the nonsense-mediated decay pathway. Genome Biol 3:reviews. 2002; 
1006:1–6.
45. Hultquist D, Passon P. Catalysis of methaemoglobin reduction by erythrocyte cytochrome b5 and 
cytochrome b5 reductase. Nature New Biol. 1971; 229:252–4. [PubMed: 4324110] 
46. Kitao T, Sugita Y, Yoneyama Y, Hattori K. Methemoglobin reductase (cytochrome b5 reductase) 
deficiency in congenital methemoglobinemia. Blood. 1974; 44:879–84. [PubMed: 4138943] 
47. Hegesh E, Hegesh J, Kaftory A. Congenital methemoglobinemia with a deficiency of cytochrome 
b5. N Eng J Med. 1986; 314:757–61.
48. Xu Y, Kiningham KK, Devalaraja MN, Yeh CC, Majima H, Kasarskis EJ, et al. An intronic NF-
kappaB element is essential for induction of the human manganese superoxide dismutase gene by 
tumor necrosis factor-alpha and interleukin-1beta. DNA Cell Biol. 1999; 18:709–22. [PubMed: 
10492402] 
Blanke et al. Page 10






















49. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, Jacobs N, et al. NF-kappaB transcription 
factor induces drug resistance through MDR1 expression in cancer cells. Oncogene. 2003; 22:90–
7. [PubMed: 12527911] 
50. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer 
subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295:2492–502. 
[PubMed: 16757721] 
51. Hall IJ, Moorman PG, Millikan RC, Newman B. Comparative analysis of breast cancer risk factors 
among African-American women and White women. Am J Epidemiol. 2005; 161:40–51. 
[PubMed: 15615914] 
52. Mayberry RM, Stoddard-Wright C. Breast cancer risk factors among black women and white 
women: similarities and differences. Am J Epidemiol. 1992; 136:1445–56. [PubMed: 1288274] 
53. Li Y, Millikan RC, Bell DA, Cui L, Tse CK, Newman B, et al. Cigarette smoking, cytochrome 
P4501A1 polymorphisms, and breast cancer among African-American and white women. Breast 
Cancer Res. 2004; 6:R460–73. [PubMed: 15217514] 
54. Mechanic L, Millikan RC, Player J, RenedeCotret A, Winkel S, Worley K, et al. Polymorphisms in 
nucleotide excision repair genes, smoking and breast cancer in African Americans and whites: a 
population-based case-control study. Carcinogenesis. 2006; 27:1377–85. [PubMed: 16399771] 
55. Terry PD, Rohan TE. Cigarette smoking and the risk of breast cancer in women: a review of the 
literature. Cancer Epidemiol Biomarkers Prev. 2002; 11:953–71. [PubMed: 12376493] 
56. Tang D, Liu JJ, Rundle A, Neslund-Dudas C, Savera AT, Bock C, et al. Grilled meat consumption 
and PhIP-DNA adducts in prostate carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2007; 
16:803–8. [PubMed: 17416774] 
57. Letasiova S, Medve'ova A, Sovcikova A, Dusinska M, Volkovova K, Mosoiu C, et al. Bladder 
cancer, a review of the environmental risk factors. Environ Health. 2012; 11(Suppl 1):S11. 
[PubMed: 22759493] 
58. Ferrucci LM, Sinha R, Huang WY, Berndt SI, Katki HA, Schoen R, et al. Meat consumption and 
the risk of incident distal colon and rectal adenoma. Br J Cancer. 2012; 106:608–16. [PubMed: 
22166801] 
59. Kurian J, Bajad S, Miller J, Chin N, Trepanier L. NADH cytochrome b5 reductase and cytochrome 
b5 catalyze the microsomal reduction of xenobiotic hydroxylamines and amidoximes in humans. J 
Pharmacol Exp Ther. 2004; 311
60. Grillo G, Turi A, Licciulli F, Mignone F, Liuni S, Banfi S, et al. UTRdb and UTRsite (RELEASE 
2010): a collection of sequences and regulatory motifs of the untranslated regions of eukaryotic 
mRNAs. Nucleic Acids Res. 2010; 38:D75–80. [PubMed: 19880380] 
61. Baird SD, Turcotte M, Korneluk RG, Holcik M. Searching for IRES. RNA. 2006; 12:1755–85. 
[PubMed: 16957278] 
Blanke et al. Page 11























Metabolism and bioactivation of carcinogenic aromatic and heterocyclic amines. Aromatic 
and heterocyclic amines may initially be detoxified by either glucuronidation or N-
acetylation (by NAT1 or NAT2). Alternatively, the parent amines can be bioactivated to 
their hydroxylamine metabolites via cytochrome P450′s (CYP1A2, 1A1, and 1B1), 
myeloperoxidases, or lactoperoxidases. Hydroxylamine metabolites are reduced back to 
their parent compound by NADH cytochrome b5 reductase (b5R) and cytochrome b5 (b5) 
[33]. Reverse reduction by the b5/b5R pathway is up to 55 times more efficient than forward 
oxidation by P450′s [34]. Hydroxylamine metabolites may also be detoxified by glutathione 
S-transferases (GST′s) or UDP-glucuronosyltransferases (UGT's), or can be further 
bioactivated by O-acetylation or O-sulfonation. This final bioactivation step can lead to 
DNA adducts via arylnitrenium ion formation.
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Table 1
Characteristics of Carolina Breast Cancer Study (CBCS) patients with invasive carcinomas and carcinoma in 
situ, and unaffected controls included in CYB5A and CYB5R3 genotyping.
Controls Cases
N % N %
African American 658 100 742 100
Median age in years (range) 50 (26–74) 51 (23-74)
Mean proportion of African ancestry 0.774 0.778
Age (years)
 <50 314 47.7 355 47.8
 >=50 344 52.3 387 52.2
Menopausal status
 Premenopausal 290 44.1 324 43.7
 Postmenopausal 368 55.9 418 56.3
Education
 <High school (HS) 198 30.1 215 29.0
 HS & Post HS 348 53.0 406 54.8
 >=College 111 16.9 120 16.2
Smoking
 Ever 262 39.8 322 43.4
 Never 396 60.2 420 56.6
Caucasian 1089 100 1204 100
Median age in years (range) 51 (21–74) 50 (24-74)
Mean proportion of African ancestry 0.066 0.064
Age (years)
 <50 491 45.1 592 49.2
 >=50 598 54.9 612 50.8
Menopausal status
 Premenopausal 456 41.9 540 44.9
 Postmenopausal 633 58.1 664 55.2
Education
 <High school 115 10.6 103 8.6
 HS & Post HS 613 56.3 671 55.7
 >=College 361 33.1 430 35.7
Smoking
 Ever 546 50.1 587 48.8
 Never 543 49.9 617 51.3
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Table 2
Single nucleotide polymorphisms in CYB5A selected for genotyping in the Carolina Breast Cancer Study 
population, along with rationale for selection.
SNP SNP ID Rationale for selection
-206G>- rs36082929 Reported in the NCBI SNP database.Within binding sites of several transcription factors (YY1, NFκ-B, 
NF-κB, NF- κA, and c-Fos).a
13T>GSer5Ala rs75160992 Found in 2 of 111 liver samples (both heterozygous African Americans) in association with outlier low 
protein expression and activity [35].
65A>GHis22Arg rs74339771 Found in 1 of 70 breast samples (heterozygous African American woman) in association with low 
protein expression and activity [36]. Predicted to be deleterious to protein function. b
I2-992C>T rs1790894 Reported in the NCBI SNP database. Within binding sites for NF κ-B. a
155G>A Arg52Lys rs1803366 Reported in the NCBI SNP database Predicted to be deleterious to protein function. c
178A>G Thr60Ala rs78009726 Found in 1 of 63 leukocyte cDNA samples in a heterozygous African American subject [59]. Variant 
protein undergoes accelerated proteasomal degradation [59].
390C>ATyr130stop rs1803364 Reported in the NCBI SNP database.Predicted to be deleterious due to stop codon. d
*246T>C rs76241580 Found in 1 of 69 liver samples (Caucasian heterozygote)in association with outlier low b5 protein 
expression andactivity; e
Located in internal ribosomal entry site [60]; may affect translation initiatio [61].
a








Unpublished data from Sacco et al. 2010.
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Table 3
Single nucleotide polymorphisms in CYB5R3 selected for genotyping in the Carolina Breast Cancer Study 
population, along with rationale for selection.
SNP SNP ID Rationale for selection
-251G>T rs73888347 Found in 1 of 69 livers in association with low (outside the 95% confidence interval of the mean) b5R 
expression and reduction activity; heterozygous African American subject. a Predicted deletion of 
VDR/CAR/PXR binding sites. b
-231C>A rs75133903 Found in 1 of 69 livers in association with low b5R expression; heterozygous Caucasian subject.a
I1M+6C>T rs8190370 Found in 1 of 69 livers, a and 2 of 70 breast samples [36], in association with low b5R expression; all 
heterozygous African American.Predicted to create a cryptic splice site.c
I1M+6072C>T rs8190414 Reported in the NCBI SNP database. Within binding sites of NFκ-B, Max. d
176G>AArg59His rs111154229 Observed in a heterozygous Caucasian liver with low b5R expression [35].
Predicted to be deleterious to protein function.e,f
I8-1676T>C rs751153 Reported in the NCBI SNP database. Within binding sites of Rad21.d
890G>AArg297His rs76458556 Observed in heterozygous Caucasian liver with low b5R expression and activity [35].
Predicted to be deleterious to protein function. g
*138G>A ss159816065 Found in 1 of 69 livers with outlier low b5R expression and activity; heterozygous African American 
subject. a
*392G>C rs7284807 Found in 5 of 69 livers with predominantly low b5R activity; all African American heterozygotes.a
*863T>C ss159830807 Found in 1 of 69 livers with low b5R expression and activity; heterozygous Caucasian subject.a
a
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Table 4
Minor allele frequencies (MAF) for CYB5A and CYB5R3 variants in African American (AfrAm) and 
Caucasian (Cauc) women from the Carolina Breast Cancer Study [37]. Subjects are cases (with a diagnosis of 
invasive breast cancer or carcinoma in situ) or controls (without a breast cancer or CIS diagnosis and 
frequency-matched by age and race).
CYB5A Minor allele frequencies Cases Minor allele frequencies Controls
AfrAm Cauc AfrAm Cauc
13 T>G(Ser5Ala) 0.0088 0.0008 0.0069 a 0.0000 a
I2-992 C>T 0.1577 0.0096 c 0.1689 0.0069 c
390 C>A 0.0000 0.0004 0.0000 0.0000
CYB5R3 Minor allele frequencies Cases Minor allele frequencies Controls
AfrAm Cauc AfrAm Cauc
-251 G>T 0.0674 0.0017 0.0727 a 0.0005 a
-231 C>A 0.0000 0.0000 0.0000 0.0009
I1M+6 C>T 0.0611 b 0.0008 0.0441a, b 0.0005 a
I1M+6072 C>T 0.0007 0.0000 0.0000 0.0000
I8-1676 T>C 0.1493 0.0025 0.1531a 0.0014 a
*138 G>A 0.0027 0.0025 0.0000 0.0028
*392 G>C 0.1154 0.0033 c 0.1353 0.0042 c
*863 T>C 0.0000 0.0000 0.0000 0.0005
a
Significantly different between AfrAm and Cauc controls (P ≤ 0.0001).
b
Significantly different between cases and controls (P < 0.05).
c
Not in HWE in Caucasians.
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